Biotechnology US pharma major Bristol-Myers Squibb today announced that the European Medicines Agency (EMA) has validated the company’s type II variation application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor (PI), and have demonstrated disease progression on the last therapy. 18 September 2018